Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China flag China · Delayed Price · Currency is CNY
17.28
+0.13 (0.76%)
Feb 24, 2026, 3:00 PM CST

Cisen Pharmaceutical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
7,8246,2216,6015,6685,9786,229
Market Cap Growth
28.67%-5.76%16.46%-5.19%-4.03%-16.98%
Enterprise Value
4,5633,7824,0823,3643,9173,923
Last Close Price
17.2813.4013.6511.4811.8712.11
PE Ratio
16.0012.2212.6616.2017.8914.20
Forward PE
-46.9546.9546.9546.9546.95
PS Ratio
2.201.561.481.391.581.70
PB Ratio
1.261.041.151.061.181.30
P/TBV Ratio
1.311.081.201.111.231.36
P/FCF Ratio
11.1613.2615.2325.4032.7427.23
P/OCF Ratio
9.6210.9014.6321.9425.5914.45
EV/Sales Ratio
1.280.950.920.831.031.07
EV/EBITDA Ratio
7.545.535.226.479.077.58
EV/EBIT Ratio
11.488.107.4111.5518.2810.96
EV/FCF Ratio
6.518.069.4115.0821.4517.15
Debt / Equity Ratio
0.010.020.030.030.030.07
Debt / EBITDA Ratio
0.070.170.220.300.330.64
Debt / FCF Ratio
0.060.250.390.710.791.44
Net Debt / Equity Ratio
-0.53-0.45-0.45-0.49-0.45-0.46
Net Debt / EBITDA Ratio
-5.47-3.92-3.33-5.05-5.28-4.26
Net Debt / FCF Ratio
-4.71-5.71-6.01-11.76-12.49-9.65
Asset Turnover
0.470.540.630.620.600.63
Inventory Turnover
2.152.392.973.112.962.75
Quick Ratio
3.322.723.023.172.862.56
Current Ratio
4.053.333.633.703.403.08
Return on Equity (ROE)
8.24%8.76%9.45%6.77%6.78%9.33%
Return on Assets (ROA)
3.29%3.92%4.87%2.76%2.14%3.82%
Return on Invested Capital (ROIC)
11.91%12.90%16.48%10.17%7.92%13.17%
Return on Capital Employed (ROCE)
6.30%7.70%9.20%5.30%4.20%7.30%
Earnings Yield
6.30%8.18%7.90%6.17%5.59%7.04%
FCF Yield
8.96%7.54%6.57%3.94%3.05%3.67%
Dividend Yield
2.19%3.28%3.19%2.92%2.53%2.11%
Payout Ratio
41.27%59.85%29.95%39.87%36.13%63.81%
Buyback Yield / Dilution
-0.89%-0.23%0.25%-0.65%0.18%-0.21%
Total Shareholder Return
1.30%3.05%3.45%2.27%2.71%1.90%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.